Inhibition of the lysophosphatidylinositol transporter abcc1 reduces prostate cancer cell growth and sensitizes to chemotherapy
Expression of ATP-binding cassette (ABC) transporters has long been implicated in cancer chemotherapy resistance. Increased expression of the ABCC subfamily transporters has been reported in prostate cancer, especially in androgen-resistant cases. ABCC transporters are known to efflux drugs but, rec...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Language: | English |
| Published: |
2020
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.11937/80686 |
| _version_ | 1848764248930385920 |
|---|---|
| author | Emmanouilidi, Aikaterini Casari, Ilaria Akkaya, B.G. Maffucci, T. Furic, L. Guffanti, F. Broggini, M. Chen, X. Maxuitenko, Y.Y. Keeton, A.B. Piazza, G.A. Linton, K.J. Falasca, Marco |
| author_facet | Emmanouilidi, Aikaterini Casari, Ilaria Akkaya, B.G. Maffucci, T. Furic, L. Guffanti, F. Broggini, M. Chen, X. Maxuitenko, Y.Y. Keeton, A.B. Piazza, G.A. Linton, K.J. Falasca, Marco |
| author_sort | Emmanouilidi, Aikaterini |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Expression of ATP-binding cassette (ABC) transporters has long been implicated in cancer chemotherapy resistance. Increased expression of the ABCC subfamily transporters has been reported in prostate cancer, especially in androgen-resistant cases. ABCC transporters are known to efflux drugs but, recently, we have demonstrated that they can also have a more direct role in cancer progression. The pharmacological potential of targeting ABCC1, however, remained to be assessed. In this study, we investigated whether the blockade of ABCC1 affects prostate cancer cell proliferation using both in vitro and in vivo models. Our data demonstrate that pharmacological inhibition of ABCC1 reduced prostate cancer cell growth in vitro and potentiated the effects of Docetaxel in vitro and in mouse models of prostate cancer in vivo. Collectively, these data identify ABCC1 as a novel and promising target in prostate cancer therapy. |
| first_indexed | 2025-11-14T11:16:21Z |
| format | Journal Article |
| id | curtin-20.500.11937-80686 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| language | eng |
| last_indexed | 2025-11-14T11:16:21Z |
| publishDate | 2020 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-806862021-01-07T07:46:47Z Inhibition of the lysophosphatidylinositol transporter abcc1 reduces prostate cancer cell growth and sensitizes to chemotherapy Emmanouilidi, Aikaterini Casari, Ilaria Akkaya, B.G. Maffucci, T. Furic, L. Guffanti, F. Broggini, M. Chen, X. Maxuitenko, Y.Y. Keeton, A.B. Piazza, G.A. Linton, K.J. Falasca, Marco ABC transporter ABCC1/MRP1 Docetaxel lysophosphatidylinositol prostate cancer Expression of ATP-binding cassette (ABC) transporters has long been implicated in cancer chemotherapy resistance. Increased expression of the ABCC subfamily transporters has been reported in prostate cancer, especially in androgen-resistant cases. ABCC transporters are known to efflux drugs but, recently, we have demonstrated that they can also have a more direct role in cancer progression. The pharmacological potential of targeting ABCC1, however, remained to be assessed. In this study, we investigated whether the blockade of ABCC1 affects prostate cancer cell proliferation using both in vitro and in vivo models. Our data demonstrate that pharmacological inhibition of ABCC1 reduced prostate cancer cell growth in vitro and potentiated the effects of Docetaxel in vitro and in mouse models of prostate cancer in vivo. Collectively, these data identify ABCC1 as a novel and promising target in prostate cancer therapy. 2020 Journal Article http://hdl.handle.net/20.500.11937/80686 10.3390/cancers12082022 eng http://creativecommons.org/licenses/by/4.0/ fulltext |
| spellingShingle | ABC transporter ABCC1/MRP1 Docetaxel lysophosphatidylinositol prostate cancer Emmanouilidi, Aikaterini Casari, Ilaria Akkaya, B.G. Maffucci, T. Furic, L. Guffanti, F. Broggini, M. Chen, X. Maxuitenko, Y.Y. Keeton, A.B. Piazza, G.A. Linton, K.J. Falasca, Marco Inhibition of the lysophosphatidylinositol transporter abcc1 reduces prostate cancer cell growth and sensitizes to chemotherapy |
| title | Inhibition of the lysophosphatidylinositol transporter abcc1 reduces prostate cancer cell growth and sensitizes to chemotherapy |
| title_full | Inhibition of the lysophosphatidylinositol transporter abcc1 reduces prostate cancer cell growth and sensitizes to chemotherapy |
| title_fullStr | Inhibition of the lysophosphatidylinositol transporter abcc1 reduces prostate cancer cell growth and sensitizes to chemotherapy |
| title_full_unstemmed | Inhibition of the lysophosphatidylinositol transporter abcc1 reduces prostate cancer cell growth and sensitizes to chemotherapy |
| title_short | Inhibition of the lysophosphatidylinositol transporter abcc1 reduces prostate cancer cell growth and sensitizes to chemotherapy |
| title_sort | inhibition of the lysophosphatidylinositol transporter abcc1 reduces prostate cancer cell growth and sensitizes to chemotherapy |
| topic | ABC transporter ABCC1/MRP1 Docetaxel lysophosphatidylinositol prostate cancer |
| url | http://hdl.handle.net/20.500.11937/80686 |